- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.19: 2 residues within 4Å:- Chain A: Y.28, N.61
Ligand excluded by PLIPNAG.20: 5 residues within 4Å:- Chain A: N.122, A.123, T.124, N.125, V.127
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain A: E.132, N.164, N.165
Ligand excluded by PLIPNAG.22: 3 residues within 4Å:- Chain A: T.108, N.234, T.236
Ligand excluded by PLIPNAG.23: 4 residues within 4Å:- Chain A: N.280, E.281, N.282
- Chain C: K.558
Ligand excluded by PLIPNAG.24: 3 residues within 4Å:- Chain A: N.331, Q.580, L.582
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain A: F.338, N.343
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: N.709, G.1131
- Chain B: D.796
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain B: Y.28, N.61
Ligand excluded by PLIPNAG.28: 5 residues within 4Å:- Chain B: N.122, A.123, T.124, N.125, V.127
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain B: E.132, N.164, N.165
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain B: T.108, N.234
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain A: K.558
- Chain B: N.280, E.281, N.282
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain B: N.331, Q.580
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain B: F.338, N.343
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain B: N.709, G.1131
- Chain C: D.796
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain C: N.122, A.123, T.124, N.125, V.127
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain C: E.132, N.164, N.165
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain C: T.108, N.234
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain C: N.280, E.281, N.282
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain C: N.331, Q.580, L.582
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain C: F.338, N.343
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain A: D.796
- Chain C: N.709, G.1131
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain D: N.36, Q.323
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain D: N.73, T.75
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain D: Q.64, Q.84, N.86, H.178
Ligand excluded by PLIPNAG.46: 2 residues within 4Å:- Chain D: N.305, M.306
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain D: N.415, W.577
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain D: S.403, N.529
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain E: N.36, Q.323
Ligand excluded by PLIPNAG.50: 3 residues within 4Å:- Chain E: K.9, N.73, T.75
Ligand excluded by PLIPNAG.51: 4 residues within 4Å:- Chain E: Q.64, Q.84, N.86, H.178
Ligand excluded by PLIPNAG.52: 3 residues within 4Å:- Chain E: N.305, M.306, W.311
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain E: F.268, N.415, W.577
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain E: S.403, N.529
Ligand excluded by PLIPNAG.55: 2 residues within 4Å:- Chain F: N.36, Q.323
Ligand excluded by PLIPNAG.56: 2 residues within 4Å:- Chain F: N.73, T.75
Ligand excluded by PLIPNAG.57: 4 residues within 4Å:- Chain F: Q.64, Q.84, N.86, H.178
Ligand excluded by PLIPNAG.58: 3 residues within 4Å:- Chain F: N.305, M.306, W.311
Ligand excluded by PLIPNAG.59: 3 residues within 4Å:- Chain F: F.268, N.415, W.577
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain F: S.403, N.529
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Mannar, D. et al., Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep (2021)
- Release Date
- 2021-12-29
- Peptides
- Spike glycoprotein: ABC
Processed angiotensin-converting enzyme 2: DEF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
F
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 42 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Mannar, D. et al., Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep (2021)
- Release Date
- 2021-12-29
- Peptides
- Spike glycoprotein: ABC
Processed angiotensin-converting enzyme 2: DEF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
F